每年專案
個人檔案
學歷
- 2000 臺灣大學醫學院藥研所博士
- 1996 臺灣大學醫學院藥研所碩士
- 1994 臺北醫學院藥學系學士
經歷
- 2023.08- 臺北醫學大學研究發展處研發長
- 2021.11- 臺北醫學大學新藥開發研究中心主任
- 2017.06- 臺北醫學大學生技醫藥商品化中心主任
- 2018.01-2023.12 臺北醫學大學藥學院院長
- 2015.08-2022.07 臺北醫學大學藥學院生技製藥研究中心主任
- 2013.09-2017.12 臺北醫學大學藥學院副院長
- 2013.08- 臺北醫學大學中草藥臨床藥物研發博士學位學程
- 2013.08- 臺北醫學大學癌症生物學與藥物研發博士學位學程
- 2012.10-2016.12 臺北醫學大學藥物有機合成核心服務實驗室主任
- 2012.08- 臺北醫學大學藥物科學學科教授
- 2012.02-2012.07 臺北醫學大學藥物科學學科副教授
- 2008.02-2012.01 臺北醫學大學藥學系副教授
- 2004.10-2008.01 臺北醫學大學藥學系助理教授
獎項
- 2019 Total Research project Budget Award - Excellence Award, Taipei Medical University
- 2019 Excellent Industry-Academia Collaboration Award, Taipei Medical University
1. EDITORIAL ADVISORY BOARD members, Journal of Medicinal Chemistry (IF = 6.259, CHEMISTRY/MEDICINAL)
2. 2015 Taipei Medical University Teaching Award
3. 2014 Taipei Biotech Awards, Gold “Industry-University Cooperation Award”
4. 2014 TienTe Lee Award, Young Scientist Award
5. 2011 Young scientist award, Ching-Kang Foundation for Pharmacy Promotion
研究興趣
- 抗癌小分子化合物設計與合成
- 有機合成
指紋
查看啟用 Jing-Ping Liou 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
- 1 類似的個人檔案
過去五年中的合作和熱門研究領域
國家/地區層面的近期外部共同作業。按一下圓點深入探索詳細資料，或
專案
- 37 已完成
-
脂肪酸代謝所調控的神經炎症在構建造成腫瘤復發之神經元-巨噬細胞-膠質瘤迴路中的角色－可穿透血腦障蔽腦障蔽且抑制惡性神經膠母細胞瘤發炎之藥物研發(2/3)
Liou, J.-P. (PI)
8/1/23 → 7/31/24
研究計畫: A - 政府部門 › b - 國家科學及技術委員會
-
-
Toll-Like Receptor 7/8 Agonists 和 EZH2 Inhibitors 對於三陰性乳癌的 dual target inhibitor 開發
Liou, J.-P. (PI)
7/1/23 → 2/29/24
研究計畫: A - 政府部門 › b - 國家科學及技術委員會
-
-
-
Correction to: The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells (Cell Death & Disease, (2013), 4, 9, (e810), 10.1038/cddis.2013.330)
Chen, M. C., Chen, C. H., Wang, J. C., Tsai, A. C., Liou, J. P., Pan, S. L. & Teng, C. M., 7月 2024, 於: Cell Death and Disease. 15, 7, 490.研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審
開啟存取 -
Design, synthesis, and biological evaluation of adenosine derivatives targeting DOT1L and HAT as anti-leukemia agents
Sethy, B., Yu, Z. Y., Narwanti, I., Upadhyay, R., Lai, M. J., Lee, S. B. & Liou, J. P., 12月 2024, 於: Bioorganic Chemistry. 153, 107771.研究成果: 雜誌貢獻 › 文章 › 同行評審
-
Dual inhibition of CYP17A1 and HDAC6 by abiraterone-installed hydroxamic acid overcomes temozolomide resistance in glioblastoma through inducing DNA damage and oxidative stress
Sharma, R., Chiang, Y. H., Chen, H. C., Lin, H. Y., Yang, W. B., Nepali, K., Lai, M. J., Chen, K. Y., Liou, J. P. & Hsu, T. I., 4月 1 2024, 於: Cancer Letters. 586, 216666.研究成果: 雜誌貢獻 › 文章 › 同行評審
2 引文 斯高帕斯（Scopus） -
Effect of Sulfotyrosine and Negatively Charged Amino Acid of Leech-Derived Peptides on Binding and Inhibitory Activity Against Thrombin
Chen, T.-Y., Shyur, E., Ma, T.-H., Wijeyewickrema, L., Lin, S.-W., Kao, M.-R., Liang, P.-H., Shie, J.-J., Chuang, E.-Y., Liou, J.-P. & Hsieh, Y. S., 2月 1 2024, 於: ChemBioChem. 25, 3, p. e202300744 e202300744.研究成果: 雜誌貢獻 › 文章 › 同行評審
開啟存取 -
First-in-Class Dual EZH2-HSP90 Inhibitor Eliciting Striking Antiglioblastoma Activity In Vitro and In Vivo
Sharma, S., Wang, S. A., Yang, W. B., Lin, H. Y., Lai, M. J., Chen, H. C., Kao, T. Y., Hsu, F. L., Nepali, K., Hsu, T. I. & Liou, J. P., 2月 22 2024, 於: Journal of Medicinal Chemistry. 67, 4, p. 2963-2985 23 p.研究成果: 雜誌貢獻 › 文章 › 同行評審
開啟存取3 引文 斯高帕斯（Scopus）
資料集
-
The anticancer effects of MPT0G211, a novel HDAC6 inhibitor, combined with chemotherapeutic agents in human acute leukemia cells
Tu, H.-J. (Contributor), Lin, Y.-J. (Contributor), Chao, M.-W. (Contributor), Sung, T.-Y. (Creator), Wu, Y.-W. (Creator), Chen, Y.-Y. (Creator), Lin, M.-H. (Contributor), Liou, J.-P. (Creator), Pan, S.-L. (Contributor) & Yang, C.-R. (Contributor), Figshare, 2018
DOI: 10.6084/m9.figshare.c.4350887.v1, https://springernature.figshare.com/collections/The_anticancer_effects_of_MPT0G211_a_novel_HDAC6_inhibitor_combined_with_chemotherapeutic_agents_in_human_acute_leukemia_cells/4350887/1
資料集: Dataset
-
Additional file 1: of Suberoylanilide hydroxamic acid represses glioma stem-like cells
Chang, K.-Y. (Creator), Wang, J.-Y. (Creator), Chuang, J.-Y. (Creator), Ko, C.-Y. (Contributor), Hsu, T.-I. (Contributor), Chang, W.-C. (Creator), Yeh, S.-H. (Contributor), Liou, J.-P. (Creator), Liu, J.-J. (Contributor) & Hsu, C.-C. (Contributor), Figshare, 2016
DOI: 10.6084/m9.figshare.c.3596465_d1.v1, https://doi.org/10.6084%2Fm9.figshare.c.3596465_d1.v1
資料集: Dataset
-
Effect of 3-subsitution of quinolinehydroxamic acids on selectivity of histone deacetylase isoforms
Lai, M.-J. (Creator), Lee, C.-H. (Creator), Chao, Y.-H. (Creator), Mehndiratta, S. (Creator), Chen, M.-C. (Creator), Liou, J.-P. (Creator) & Lee, H.-Y. (Creator), Taylor & Francis, 2020
DOI: 10.6084/m9.figshare.13207104.v1, https://tandf.figshare.com/articles/journal_contribution/Effect_of_3-subsitution_of_quinolinehydroxamic_acids_on_selectivity_of_histone_deacetylase_isoforms/13207104/1
資料集: Dataset
-
Additional file 3: of Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Chao, M.-W. (Contributor), Chang, L.-H. (Contributor), Tu, H.-J. (Contributor), Chang, C.-D. (Contributor), Lai, M.-J. (Contributor), Chen, Y.-Y. (Creator), Liou, J.-P. (Creator), Teng, C.-M. (Contributor) & Pan, S.-L. (Contributor), Figshare, 2019
DOI: 10.6084/m9.figshare.8202890.v1, https://springernature.figshare.com/articles/Additional_file_3_of_Combination_treatment_strategy_for_pancreatic_cancer_involving_the_novel_HDAC_inhibitor_MPT0E028_with_a_MEK_inhibitor_beyond_K-Ras_status/8202890/1
資料集: Dataset
-
Novel microtubule inhibitor MPT0B098 inhibits hypoxia-induced epithelial-to-mesenchymal transition in head and neck squamous cell carcinoma
Tsai, I.-T. (Contributor), Kuo, C.-C. (Contributor), Liou, J.-P. (Creator) & Chang, J.-Y. (Contributor), Figshare, 2018
DOI: 10.6084/m9.figshare.c.4052207.v1, https://figshare.com/collections/Novel_microtubule_inhibitor_MPT0B098_inhibits_hypoxia-induced_epithelial-to-mesenchymal_transition_in_head_and_neck_squamous_cell_carcinoma/4052207/1
資料集: Dataset